Status:
RECRUITING
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
Lead Sponsor:
Galderma R&D
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
12+ years
Brief Summary
The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at ...
Detailed Description
This prospective, multicenter, non-interventional study (NIS) seeks to evaluate treatment with nemolizumab of moderate-to-severe AD in adolescents and adults over an approximately 12-month period usin...
Eligibility Criteria
Inclusion
- Participants who, according to the treating physician's decision and in line with the local package label, start treatment with nemolizumab (Nemluvio®).
- Adolescent and adult participants aged \>=12 years with moderate-to-severe AD.
- Participants who signed the written informed consent form (ICF) or had it signed by their legal representative.
Exclusion
- Have contraindication(s) for the use of nemolizumab (Nemluvio®) according to the local package label.
- Participants who received treatment with a drug under clinical development/investigation within 3 months prior to baseline.
- Participants who received nemolizumab previously.
- Participants who are mentally, physically, or linguistically unable to understand the content of the ICF and/or to complete the study questionnaires.
Key Trial Info
Start Date :
July 14 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 30 2027
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT06988605
Start Date
July 14 2025
End Date
November 30 2027
Last Update
November 19 2025
Active Locations (111)
Enter a location and click search to find clinical trials sorted by distance.
1
Galderma Investigational Site - 8893
Birmingham, Alabama, United States, 35244
2
Galdrma Investigational Site - 7077
Phoenix, Arizona, United States, 85006-2754
3
Galderma Investigational Site 7060
Phoenix, Arizona, United States, 85008-3884
4
Galderma Investigational Site - 8535
Phoenix, Arizona, United States, 85032-2238